AUSTRALIAN PRODUCT INFORMATION DOVATO (dolutegravir/lamivudine fixed-dose combination) film-coated tablets 1 NAME OF THE MEDICIN
![Dosing Considerations | See Boxed Warning for TRIUMEQ & TRIUMEQ PD (abacavir, dolutegravir, lamivudine) Dosing Considerations | See Boxed Warning for TRIUMEQ & TRIUMEQ PD (abacavir, dolutegravir, lamivudine)](https://i-cf65.gskstatic.com/content/dam/cf-viiv/triumeq-hcp/master/triumeq_pd_chart_desktop_v4.png?auto=format)
Dosing Considerations | See Boxed Warning for TRIUMEQ & TRIUMEQ PD (abacavir, dolutegravir, lamivudine)
![Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV](https://www.thelancet.com/cms/attachment/4dcbeea0-d1ac-4fc6-9a1d-4e40e9d1d7fa/gr2_lrg.jpg)
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV
![Table 5 from Dolutegravir (DTG) Based Fixed Dose Combination (FDC) of Tenofovir/Lamivudine/Dolutegravir (TLD) and Viral Load Suppression in Children in Port Harcourt, Nigeria | Semantic Scholar Table 5 from Dolutegravir (DTG) Based Fixed Dose Combination (FDC) of Tenofovir/Lamivudine/Dolutegravir (TLD) and Viral Load Suppression in Children in Port Harcourt, Nigeria | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cb00916211b891dbe206930c27fcd5421b4559e3/6-Table5-1.png)
Table 5 from Dolutegravir (DTG) Based Fixed Dose Combination (FDC) of Tenofovir/Lamivudine/Dolutegravir (TLD) and Viral Load Suppression in Children in Port Harcourt, Nigeria | Semantic Scholar
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS - Document - Gale Academic OneFile
![New approaches for paediatric dosing: abacavir in newborns, doubling dolutegravir with rifampicin | aidsmap New approaches for paediatric dosing: abacavir in newborns, doubling dolutegravir with rifampicin | aidsmap](https://www.aidsmap.com/sites/default/files/styles/aidsmap_medium_crop/public/2020-03/paediatric-dosing-article.png?itok=lZqnGk_u)
New approaches for paediatric dosing: abacavir in newborns, doubling dolutegravir with rifampicin | aidsmap
![A single dose of ultra-LA dolutegravir protects against multiple high... | Download Scientific Diagram A single dose of ultra-LA dolutegravir protects against multiple high... | Download Scientific Diagram](https://www.researchgate.net/publication/328147212/figure/fig4/AS:958879806550024@1605626169280/A-single-dose-of-ultra-LA-dolutegravir-protects-against-multiple-high-dose-HIV-1.png)
A single dose of ultra-LA dolutegravir protects against multiple high... | Download Scientific Diagram
![Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV](https://www.thelancet.com/cms/attachment/433edd2b-fff4-445f-b185-84f12030ea5b/gr1_lrg.gif)
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV
![Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans | Antimicrobial Agents and Chemotherapy Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans | Antimicrobial Agents and Chemotherapy](https://journals.asm.org/cms/10.1128/AAC.00292-13/asset/3703e98b-e5bb-4d2f-b10d-d176b3a2b90a/assets/graphic/zac9991019880006.jpeg)
Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans | Antimicrobial Agents and Chemotherapy
AUSTRALIAN PRODUCT INFORMATION TIVICAY (dolutegravir) film-coated tablets 1 NAME OF THE MEDICINE 2 QUALITATIVE AND QUANTITATIVE
![Figure 2 from Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. | Semantic Scholar Figure 2 from Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2ebaaf62e2b7565bda347ab2b3c11ae21e0fe00a/4-Figure2-1.png)
Figure 2 from Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. | Semantic Scholar
![Dolutegravir mean plasma concentration versus time profiles by weight... | Download Scientific Diagram Dolutegravir mean plasma concentration versus time profiles by weight... | Download Scientific Diagram](https://www.researchgate.net/publication/343434086/figure/fig1/AS:929201238593537@1598550247348/Dolutegravir-mean-plasma-concentration-versus-time-profiles-by-weight-band-and-dose-30-mg.png)
Dolutegravir mean plasma concentration versus time profiles by weight... | Download Scientific Diagram
![Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV](https://www.thelancet.com/cms/attachment/8629ef3a-1809-4aa9-8364-a43750f744fa/gr1_lrg.gif)